

# Rowan E Miller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3544715/publications.pdf>

Version: 2024-02-01

18  
papers

209  
citations

1163117

8  
h-index

1058476

14  
g-index

18  
all docs

18  
docs citations

18  
times ranked

376  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers. <i>Cancer Discovery</i> , 2020, 10, 1528-1543.	9.4	82
2	Targeted therapies in gynaecological cancers. <i>Histopathology</i> , 2020, 76, 157-170.	2.9	30
3	PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	18
4	Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e259-e268.	3.8	14
5	Olaparib maintenance for first-line treatment of ovarian cancer: Will SOLO1 reset the standard of care?. <i>Future Oncology</i> , 2019, 15, 1845-1853.	2.4	12
6	Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. <i>European Urology Focus</i> , 2017, 3, 621-628.	3.1	10
7	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BRCA1/2-mutated ovarian tumours: definition of homologous recombination deficiency?. <i>Current Opinion in Oncology</i> , 2020, 32, 442-450.	2.4	10
8	The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 619-27.	0.3	8
9	Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 271, 138-144.	1.1	6
10	The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 704-11.	0.3	5
11	PARP inhibitors and immunotherapy in ovarian and endometrial cancers. <i>British Journal of Radiology</i> , 2021, 94, 20210002.	2.2	4
12	Targeting HPV in gynaecological cancers – Current status, ongoing challenges and future directions. <i>Women's Health</i> , 2020, 16, 174550652096170.	1.5	3
13	Diagnosis and management of penile cancer. <i>Trends in Urology &amp; Men's Health</i> , 2016, 7, 17-20.	0.4	2
14	Body Mass Index and Outcomes in Germ-Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 283-290.	1.9	2
15	COVID-19, the Future Vaccine and What It Means for Cancer Patients on Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 631611.	2.8	2
16	Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 506-510.	2.0	1
17	The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers. <i>Gynecologic Oncology</i> , 2017, 144, 8-10.	1.4	0
18	Outcome of patients with advanced endometrial and cervical cancer treated in a phase 1 unit. <i>Journal of Clinical Oncology</i> , 2017, 35, 5597-5597.	1.6	0